Background:The safety and efficacy of the dinoprostone vaginal insert for labor induction in women with prelabor rupture of membranes (PROM) remains uncertain. This study compared clinical outcomes between women with PROM and those with intact membranes.Methods:In this single-centre retrospective study, singleton pregnancies at ≥37 weeks of gestation induced with a dinoprostone vaginal insert between January 2020 and June 2025 were categorized as PROM (n = 42) or controls (n = 84). Demographic characteristics, cervical status, labor characteristics, delivery mode, maternal complications, as well as neonatal outcomes were analyzed using the t-test or Mann-Whitney U test for continuous variables and the chi-square or Fisher’s exact test for categorical variables, with a significance level of α = 0.05. The study was approved by the institutional ethics committee (Approval No.: 2026/6295; Application ID: 29133).Results:Gestational age at delivery was significantly lower in the PROM group than in the control group (37.70 ± 1.17 vs. 39.54 ± 1.39 weeks; p < 0.001). Although pre-induction cervical dilatation was greater in the PROM group, post-induction cervical dilatation and cervical effacement were significantly lower than those in the control group (both p < 0.001). The overall cesarean delivery rate was higher in the PROM group, primarily driven by an increased incidence of cesarean delivery due to fetal distress (35.7% vs. 16.7%; p = 0.008). Tachysystole was rare in both groups (0% vs. 1.2%; p = 0.478). No cases of postpartum hemorrhage or third-degree perineal lacerations occurred, and hemoglobin concentration and blood transfusion rates were comparable between groups. Neonates in the PROM group had significantly lower birth weights (2770.60 ± 447.30 g vs. 3321.20 ± 344.50 g; p < 0.001) and lower 5-minute Apgar scores (8.33 ± 1.00 vs. 9.25 ± 0.65; p < 0.001).Conclusions:Pregnancies complicated by PROM were associated with a reduced cervical response to dinoprostone, higher cesarean delivery rates, primarily due to fetal distress, and less favorable neonatal outcomes, whereas maternal safety outcomes appeared acceptable. Careful patient selection and close intrapartum monitoring are recommended when using dinoprostone for labor induction in women with PROM.
20 December 2025 in Middle East Fertility Society Journal
Objective: This study aimed to evaluate the impact of different treatment modalities—expectant management, methotrexate (MTX), and laparoscopic salpingectomy—on the future fertility of women treated for tubal ectopic pregnancies (EP). The primary outcome was to evaluate the mean time to conception, and the secondary outcome was to evaluate live birth rates and the risk of recurrent ectopic pregnancy (REP) between treatment groups. Methods: A retrospective analysis was conducted involving 121 women treated for tubal EP from January 2020 to November 2024. The study analyzed fertility outcomes based on the treatment modality received, which included expectant management, MTX, and laparoscopic salpingectomy. Data were collected through hospital records. Results: The time to clinical pregnancy was 255 (60–390) days in the expectant group, 270 (60-1080) days in the MTX group, and 255 (90-1440) days in the laparoscopic salpingectomy group. Median time to achieve pregnancy was 270 (95% CI: 222–318) days for all the treatment groups. No significant differences were found in the time to pregnancy across the treatment groups ( p = 0.274). Out of 121 patients, 58 (47.9%) achieved pregnancy, of which 33 (27.2%) resulted in live births. Live birth rates were 75%, 58.3%, and 50% in the expectant management, MTX, and laparoscopic salpingectomy groups, respectively. Live birth rates also did not differ between the three treatment groups ( p = 0.437). All the three treatment modalities did not show a statistically significant impact on the rates of REP ( p = 0.42). Conclusion: We found no significant differences in time-to-pregnancy or live birth rates among expectant, MTX, and laparoscopic salpingectomy management for tubal EP. Given EP’s significant impact on fertility in reproductive-aged women, studies comparing treatment effects on future fertility are clinically valuable.